SC
ABVX

Steven Cohen’s Abivax ABVX Stock Holding History

Steven Cohen’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Sell
800
-8,700
-92% -$985K ﹤0.01% 3685
2026
Q1 		$1.06M Sell
9,500
-490,500
-98% -$58M ﹤0.01% 2731
2025
Q4 		$67.4M Buy
+500,000
New +$54.6M 0.08% 296

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steven Cohen's ABVX Position: Q2 2026 in Review

Steven Cohen reduced its Abivax (ABVX) stake by 99% in Q2 2026, selling an estimated $71.6M and leaving 5,028 shares worth $670K. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Steven Cohen first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $325M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Steven Cohen held 5,028 shares of Abivax worth $670K as of Q2 2026.
  • Steven Cohen sold 632,708 Abivax shares in Q2 2026, an estimated $71.6M.
  • Abivax made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3038 holding.
  • Steven Cohen first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • Steven Cohen's Abivax position peaked at $325M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.